Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome (Community Letter)
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Updates on Program & Risk Mitigation Strategies (Community Letter)
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
Update on Patient SAE & Discontinuation of High Dose Protocol (Community Letter)
Update on Patient SAE (Community Letter)
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome